Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 1:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 499 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Surgical resection (standard of care) Clear all
Completed No phase listed Observational Results available

Molecular Profiling in Guiding Individualized Treatment Plan in Adults With Recurrent/Progressive Glioblastoma

NCT02060890
View directory record Official record
Conditions
Adult Glioblastoma
Interventions
specialized tumor board recommendation
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Oct 14, 2026, 1:50 AM EDT
Completed Not applicable Interventional

Intravital Microscopy in Identifying Tumor Vessels in Patients With Stage IB-IIIC Melanoma Undergoing Sentinel Lymph Node Biopsy

NCT02857374
View directory record Official record
Conditions
Stage IB Skin Melanoma, Stage IIA Skin Melanoma, Stage IIB Skin Melanoma, Stage IIC Skin Melanoma, Stage IIIA Skin Melanoma, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma
Interventions
Diagnostic Microscopy, Fluorescein Sodium Injection, Laboratory Biomarker Analysis, Sentinel Lymph Node Biopsy
Procedure · Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 1, 2022 · Synced Oct 14, 2026, 1:50 AM EDT
Completed Phase 2 Interventional

Compare Outcomes Between Two Acellular Dermal Matrices

NCT02891759
View directory record Official record
Conditions
Breast Cancer
Interventions
Alloderm RTU, Cortiva 1mm Allograft Dermis, Skin or nipple-sparing mastectomy, Breast Q, Surgery
Other · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
22 Years to 70 Years · Female only
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 14, 2026, 1:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Safety Study of SIC 8000 in Subjects Undergoing Endoscopic Mucosal Resection (EMR) of Colonic Lesions Equal to or Larger Than 2 cm

NCT02654418
View directory record Official record
Conditions
Adenomas
Interventions
Endoscopic Mucosal Resection of large colon polyps (greater than or equal to 20 mm in size)
Procedure
Lead sponsor
Cosmo Technologies Ltd
Industry
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
3
States / cities
Jacksonville, Florida • Indianapolis, Indiana • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 5, 2017 · Synced Oct 14, 2026, 1:50 AM EDT
Terminated Phase 2 Interventional

Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer

NCT03979508
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Breast Ductal Carcinoma In Situ, Breast Fibrocystic Change, Breast Lobular Carcinoma In Situ, Invasive Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
Interventions
Abemaciclib, Therapeutic Conventional Surgery
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 14, 2026, 1:50 AM EDT
Recruiting Not applicable Interventional

Ultrasound-Guided Versus Standard Margin Selection in Ileocecal Resection of Terminal Ileal CD

NCT07680283
View directory record Official record
Conditions
Crohn's Disease (CD)
Interventions
IOUS-guided margin selection
Device
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 14, 2026, 1:50 AM EDT
Suspended No phase listed Observational

Longitudinal Assessment of Marrow and Blood in Patients With Glioblastoma

NCT04657146
View directory record Official record
Conditions
Glioblastoma
Interventions
Biorepository
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 14, 2026, 1:50 AM EDT
Not yet recruiting Phase 3 Interventional

PH Weighted Chemical Exchange Saturation Transfer MRI-Based Surgical Resection to Improve Survival in Patients With Glioblastoma

NCT06448286
View directory record Official record
Conditions
Glioblastoma
Interventions
Chemical Exchange Saturation Transfer Magnetic Resonance Imaging, Contrast-enhanced Magnetic Resonance Imaging, Magnetic Resonance Imaging, Radiation Therapy, Surgical Procedure, Temozolomide
Procedure · Radiation · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 14, 2026, 1:50 AM EDT
Recruiting No phase listed Observational

Norris ORIEN Total Cancer Care

NCT02970045
View directory record Official record
Conditions
Cancer Risk, Malignant Neoplasm
Interventions
Biospecimen Collection, Evaluation of Cancer Risk Factors, Medical Chart Review, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2037
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 14, 2026, 1:50 AM EDT
Completed No phase listed Observational

Probe-based Volumetric Laser Endomicroscopy (pVLE) of Endoscopic Mucosal Resection (EMR) Tissue in Patients With Barrett's Dysplasia

NCT02366039
View directory record Official record
Conditions
Barrett's Esophagus With High Grade Dsyplasia, Early Esophageal Cancer
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 14, 2026, 1:50 AM EDT
Not listed Phase 4 Interventional

Pilot Study Evaluating the Optimization of the ORBEYE Blue Light Filter During Fluorescence-Guided Resection of Gliomas

NCT04937244
View directory record Official record
Conditions
Malignant Glioma of Brain
Interventions
5ALA exoscopic fluorescence filter
Diagnostic Test
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Oct 14, 2026, 1:50 AM EDT
Recruiting Phase 1Phase 2 Interventional

Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer

NCT06782932
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
AGEN2373, Balstilimab, Cyclophosphamide, GVAX, AGEN2373 (RP2D), mKRASvax
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Oct 14, 2026, 1:50 AM EDT
Recruiting Phase 1 Interventional

Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells

NCT06186401
View directory record Official record
Conditions
EGFR Gene Mutation, Glioblastoma, MGMT-Unmethylated Glioblastoma, Recurrent Glioblastoma
Interventions
E-SYNC T Cells, Cyclophosphamide (non-investigational), Fludarabine (non-investigational), Leukapheresis, Surgical resection
Biological · Drug · Procedure
Lead sponsor
Hideho Okada, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 14, 2026, 1:50 AM EDT
Recruiting Phase 3 Interventional

Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ

NCT04722692
View directory record Official record
Conditions
DCIS, Breast Cancer, Breast Neoplasms, Sentinel Lymph Node
Interventions
Delayed SLND, Late SLND
Diagnostic Test
Lead sponsor
Uppsala University
Other
Eligibility
18 Years and older · Female only
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 3, 2023 · Synced Oct 14, 2026, 1:50 AM EDT
Active, not recruiting No phase listed Observational

Surgery Versus Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer

NCT05183932
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Non-small Cell Lung Cancer
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
446 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
7
States / cities
Atlanta, Georgia • Urbana, Illinois • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 14, 2026, 1:50 AM EDT
Completed Phase 3 Interventional

Acute Normovolemic Hemodilution Versus Standard Intraoperative Management in Patients Having Hepatic Resection and Pancreaticoduodenectomy

NCT00200148
View directory record Official record
Conditions
Pancreaticoduodenectomy, Hepatectomy
Interventions
Normovolemic Hemodilution (ANH), Standard of care
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 14, 2026, 1:50 AM EDT
Recruiting Not applicable Interventional

Rapid Evacuation and Access of Cerebral Hemorrhage Trial

NCT06870812
View directory record Official record
Conditions
Stroke Hemorrhagic
Interventions
Surgical management, Medical Management
Procedure · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 70 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
24
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Palo Alto, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 14, 2026, 1:50 AM EDT
Active, not recruiting Phase 3 Interventional

A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features

NCT06564844
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Datopotamab Deruxtecan, Rilvegostomig, Carboplatin, Cisplatin, Etoposide, Pemetrexed, Vinorelbine, UFT
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
37
States / cities
Tucson, Arizona • Duarte, California • Glendale, California + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 14, 2026, 1:50 AM EDT
Recruiting Phase 1Phase 2 Interventional

Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas

NCT07468136
View directory record Official record
Conditions
Anaplastic Oligodendroglioma, Astrocytoma, IDH-Mutant, Grade 3, Astrocytoma, IDH-Mutant, Grade 4, Diffuse Astrocytoma, Glioblastoma, IDH-Wildtype, Malignant Glioma
Interventions
Biospecimen Collection, Eflornithine, Lumbar Puncture, Magnetic Resonance Imaging, Retifanlimab, Tumor Resection
Procedure · Drug · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 14, 2026, 1:50 AM EDT
Terminated Phase 3 Interventional Results available

Fluorescence Imaging of Carcinoma During Breast Conserving Surgery

NCT04815083
View directory record Official record
Conditions
Breast Neoplasm Female, Breast Cancer
Interventions
Aminolevulinic Acid Hydrochloride, Eagle V1.2 Imaging System, Placebo
Drug · Device
Lead sponsor
SBI ALApharma Canada, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
7
States / cities
Stamford, Connecticut • Clearwater, Florida • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Oct 14, 2026, 1:50 AM EDT
Recruiting Phase 1Phase 2 Interventional

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

NCT06239272
View directory record Official record
Conditions
Adipocytic Neoplasm, Liposarcoma, Atypical Fibroxanthoma, Angiomatoid Fibrous Histiocytoma, Fibrosarcoma NOS, Myxofibrosarcoma, Angiosarcoma, Osteosarcoma, Extraskeletal, Dedifferentiated Liposarcoma, Myxoid Liposarcoma, Pleomorphic Liposarcoma, Myxoid Pleomorphic Liposarcoma, Low Grade Fibromyxoid Sarcoma, Sclerosing Epithelioid Fibrosarcoma, Malignant Tenosynovial Giant Cell Tumor of Soft Tissue, Epithelioid Hemangioendothelioma, Glomus Tumor, Inflammatory Leiomyosarcoma, Leiomyosarcoma, Ossifying Fibromyxoid Tumor, Malignant, Myoepithelioma, Synovial Sarcoma, Epithelioid Sarcoma, Perineurioma, Malignant, Clear Cell Sarcoma, Extraskeletal Myxoid Chondrosarcoma, Granular Cell Tumor, Malignant, Melanotic Malignant Nerve Sheath Tumor, Malignant Peripheral Nerve Sheath Tumor, Perivascular Epithelioid Tumor, Malignant, Intimal Sarcoma, Myoepithelial Carcinoma, Undifferentiated Sarcoma, Pleomorphic Sarcoma, Undifferentiated, Round Cell Sarcoma, Undifferentiated, NTRK-Rearranged Spindle Cell Neoplasm, Phosphaturic Mesenchymal Tumor, Malignant, Round Cell Sarcoma, Well Differentiated Liposarcoma, Giant Cell Tumor of Soft Parts NOS, Low Grade Myofibroblastic Sarcoma, Dermatofibrosarcoma Protuberans, Fibrosarcomatous
Interventions
Surgical resection, Proton beam radiation therapy, Pazopanib, Ifosfamide, Doxorubicin, Selinexor
Procedure · Radiation · Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 30 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2037
U.S. locations
7
States / cities
Atlanta, Georgia • Chicago, Illinois • Baton Rouge, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 14, 2026, 1:50 AM EDT
Recruiting Phase 2 Interventional

Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors

NCT04165772
View directory record Official record
Conditions
Rectal Adenocarcinoma, Clinical Stage: Stage II (T3-4, N-), Stage III (Any T, N+), Solid Tumor, Solid Tumor, Adult
Interventions
TSR-042 or Dostarlimab, capecitabine or 5-FU, Intensity Modulated Radiation Therapy (IMRT)
Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
10
States / cities
Hartford, Connecticut • Miami, Florida • Basking Ridge, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 14, 2026, 1:50 AM EDT
Recruiting Phase 1 Interventional

XL092 and Cemiplimab in BRAF WT Thyroid Cancer

NCT06902376
View directory record Official record
Conditions
Anaplastic Thyroid Cancer, Thyroid Cancer, BRAF Mutation-Related Tumors
Interventions
Cemiplimab, XL092
Biological · Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 14, 2026, 1:50 AM EDT
Recruiting Phase 1Phase 2 Interventional

Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma

NCT04977375
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Pembrolizumab, Stereotactic Radiation Therapy, Surgical Resection
Drug · Radiation · Procedure
Lead sponsor
Chirag G. Patil
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 14, 2026, 1:50 AM EDT